|
Valoración de DCF de Nevro Corp. (NVRO)
US | Healthcare | Medical - Devices | NYSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Nevro Corp. (NVRO) Bundle
¡Mejore sus opciones de inversión con la calculadora DCF de Nevro Corp. (NVRO)! Utilice datos financieros auténticos para Nevro, ajuste las proyecciones y gastos de crecimiento, y observe instantáneamente cómo estas modificaciones afectan el valor intrínseco de Nevro Corp. (NVRO).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 390.3 | 362.0 | 386.9 | 406.4 | 425.2 | 494.6 | 575.2 | 669.1 | 778.3 | 905.3 |
| Revenue Growth, % | 0 | -7.23 | 6.87 | 5.03 | 4.63 | 16.32 | 16.32 | 16.32 | 16.32 | 16.32 |
| EBITDA | -83.4 | -52.2 | -102.4 | 21.0 | -78.3 | -74.7 | -86.9 | -101.0 | -117.5 | -136.7 |
| EBITDA, % | -21.36 | -14.42 | -26.47 | 5.17 | -18.42 | -15.1 | -15.1 | -15.1 | -15.1 | -15.1 |
| Depreciation | 7.8 | 8.2 | 8.7 | 10.3 | 11.5 | 11.6 | 13.5 | 15.7 | 18.3 | 21.3 |
| Depreciation, % | 2 | 2.26 | 2.24 | 2.54 | 2.71 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 |
| EBIT | -91.2 | -60.4 | -111.1 | 10.7 | -89.8 | -86.3 | -100.4 | -116.8 | -135.8 | -158.0 |
| EBIT, % | -23.36 | -16.68 | -28.71 | 2.63 | -21.13 | -17.45 | -17.45 | -17.45 | -17.45 | -17.45 |
| Total Cash | 237.8 | 588.0 | 362.0 | 374.4 | 322.7 | 417.9 | 486.1 | 565.4 | 657.7 | 765.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 82.8 | 77.7 | 70.5 | 78.9 | 79.4 | 97.9 | 113.9 | 132.5 | 154.1 | 179.2 |
| Account Receivables, % | 21.23 | 21.45 | 18.22 | 19.42 | 18.67 | 19.8 | 19.8 | 19.8 | 19.8 | 19.8 |
| Inventories | 91.6 | 83.3 | 93.5 | 99.6 | 118.7 | 121.7 | 141.6 | 164.7 | 191.6 | 222.8 |
| Inventories, % | 23.47 | 23.01 | 24.17 | 24.52 | 27.91 | 24.62 | 24.62 | 24.62 | 24.62 | 24.62 |
| Accounts Payable | 13.7 | 23.1 | 32.0 | 26.8 | 22.5 | 29.7 | 34.6 | 40.2 | 46.8 | 54.4 |
| Accounts Payable, % | 3.51 | 6.38 | 8.27 | 6.61 | 5.3 | 6.01 | 6.01 | 6.01 | 6.01 | 6.01 |
| Capital Expenditure | -3.5 | -6.0 | -12.3 | -7.5 | -8.6 | -9.5 | -11.1 | -12.9 | -15.0 | -17.4 |
| Capital Expenditure, % | -0.88967 | -1.66 | -3.19 | -1.86 | -2.02 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 |
| Tax Rate, % | 5.77 | 5.77 | 5.77 | 5.77 | 5.77 | 5.77 | 5.77 | 5.77 | 5.77 | 5.77 |
| EBITAT | -92.6 | -61.0 | -111.5 | 7.5 | -84.7 | -80.2 | -93.3 | -108.5 | -126.2 | -146.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -249.0 | -36.0 | -109.3 | -9.4 | -105.5 | -92.4 | -121.8 | -141.7 | -164.8 | -191.7 |
| WACC, % | 6.1 | 6.1 | 6.1 | 5.48 | 5.98 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -589.2 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -199 | |||||||||
| Terminal Value | -10,227 | |||||||||
| Present Terminal Value | -7,661 | |||||||||
| Enterprise Value | -8,250 | |||||||||
| Net Debt | 118 | |||||||||
| Equity Value | -8,367 | |||||||||
| Diluted Shares Outstanding, MM | 36 | |||||||||
| Equity Value Per Share | -232.55 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Nevro Corp.'s (NVRO) financial data pre-filled to expedite your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive Data: Nevro Corp.’s (NVRO) extensive historical financial records and pre-filled forecasts.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Insights: Instantly view Nevro Corp.’s (NVRO) intrinsic value updates as you make changes.
- Intuitive Visualizations: Engaging dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download the Template: Get instant access to the Excel-based NVRO DCF Calculator.
- Input Your Assumptions: Adjust yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Nevro Corp.'s intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose This Calculator for Nevro Corp. (NVRO)?
- Designed for Experts: A sophisticated tool utilized by healthcare analysts, investors, and financial advisors.
- Comprehensive Data: Nevro’s historical and projected financials are preloaded for enhanced accuracy.
- Forecast Scenarios: Effortlessly simulate various financial forecasts and assumptions.
- Detailed Outputs: Automatically calculates intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance makes navigating the calculator straightforward.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Nevro Corp. (NVRO) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Nevro Corp. (NVRO).
- Consultants: Deliver professional valuation insights for Nevro Corp. (NVRO) to clients quickly and accurately.
- Business Owners: Understand how companies like Nevro Corp. (NVRO) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Nevro Corp. (NVRO).
What the Template Contains
- Pre-Filled Data: Includes Nevro Corp.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Nevro Corp.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.